Company intelligence / Profile preview

Tanvex BioPharma

Taipei, Taipei City, Taiwantanvexbiologics.com.tw ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Tanvex has achieved regulatory approvals for its biosimilar filgrastim-txid in both Canada and the United States. Its trastuzumab biosimilar candidate TX05 has completed a global Phase III trial with positive efficacy and safety data; BLA resubmission was accepted by the FDA in August/July 2024. Other pipeline assets include biosimilars to bevacizumab, pertuzumab, and adalimumab at various stages from preclinical to pending approval.

Therapeutic areas: HematologyImmunologyOncology
Modalities: BiosimilarMonoclonal antibodyRecombinant protein
Industry: Biotech

Partnerships

Bora Pharmaceuticals strategic alliance announced Aug.2024Service contract with OBI Pharma June2021Patent license agreements with Amgen & Genentech for certain programs

Beyond the preview

Go deeper on Tanvex BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tanvex BioPharma.

Explore the full profile